High Vision
Schedule an appointment
Choose how to contact the office.
Choose how to contact the office.
In brief: Diseases of the retina, such as wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion, cause abnormal blood vessels to continuously leak fluid. Antiangiogenic medications (anti-VEGF) control this process, but do not eliminate the underlying cause; repeated appointments and OCT monitoring are therefore needed to adjust treatment to each eye’s individual response.
Learning that your eye needs several injections can cause uncertainty. It is understandable to wonder how many you will need, whether the treatment is working, and when it will end. The information that follows is intended to answer these questions clearly and directly, based on the available evidence.
Repeated appointments for administering antiangiogenic medications are one of the most common questions among patients with retinal vascular diseases: Why isn’t one visit enough? The answer lies in the chronic nature of the problem, not in a failure of the treatment.
The root cause is a protein called VEGF (vascular endothelial growth factor), which the eye produces in excess when tissues do not receive enough oxygen. This protein stimulates the formation of fragile, permeable blood vessels that leak fluid into the retina, damaging central vision.
The diseases in which this mechanism occurs most often are:
Laser treatment, once the standard of care for these conditions, has largely been replaced by intravitreal anti-VEGF injections. However, this treatment requires frequent injections to maintain its results, since macular edema is typically a chronic condition that can lead to permanent vision loss if it is not controlled. (Treatment of Macular Edema in Vascular Retinal Diseases: A 2021 Update)
Antiangiogenic medications slow the disease, but do not cure it. For this reason, these treatments are generally ongoing. (Comparison of Anti-VEGF Treatments for Wet AMD - American Academy of Ophthalmology)
An antiangiogenic medication blocks the action of VEGF inside the eye. When injected directly into the vitreous—the gel-like substance inside the eye—it acts locally, reducing systemic effects. This is an outpatient microinjection performed with topical anesthesia. The medication acts directly on the retina, slowing the growth of abnormal blood vessels or reducing edema. Antiangiogenic medications stop the formation of new abnormal blood vessels. (Intravitreal Injections for the Retina)
Most treatment plans begin with a loading phase: generally three to four monthly doses, given four weeks apart. This initial series is designed to achieve maximum VEGF suppression and dry the retina quickly. Consistent attendance during this phase is important because it lays the foundation for the long-term treatment response. (Anti-VEGF Injections for Macular Degeneration: A Patient Guide)
What patients can expect: the injection takes a few minutes and is performed in a controlled setting. Most people report minimal discomfort. Vision may be slightly blurry on the day of the procedure.
The American Academy of Ophthalmology notes: “Many of my patients are nervous the first time, but by the second treatment they feel much more confident in the process and its effectiveness.” — a quote from a specialist cited by the AAO in its patient guide (aao.org).
There is no fixed number. The number of injections depends on the disease, its severity, and, above all, how each eye responds to treatment. This is central to understanding follow-up.
The recommended frequency of these injections ranges from every few weeks to every few months. The interval varies from case to case and according to the response to a particular medication. Patients are likely to need multiple doses over many months. (Comparison of Anti-VEGF Treatments for Wet AMD - American Academy of Ophthalmology)
In real-world cohorts, more frequent treatment is associated with better visual outcomes. With an appropriate injection frequency, nearly 90% of eyes had stable or improved vision over the course of one year. (Anti-VEGF injection frequency correlates with visual acuity outcomes in pro re nata neovascular AMD treatment) (Wecker et al., Scientific Reports, 2019; DOI: 10.1038/s41598-019-38934-8).
The following table compares the most common conditions requiring anti-VEGF treatment in terms of typical treatment patterns:
Condition: Wet AMD
Typical loading phase: 3–4 monthly injections
Approximate maintenance: Every 4 to 16 weeks, depending on response
Interval-determining factor: Presence of fluid on OCT
Condition: Diabetic macular edema
Typical loading phase: 3–5 monthly injections
Approximate maintenance: 2.2 to 4.4 injections per year in real-world practice
Interval-determining factor: Glycemic control and retinal response
Condition: Retinal vein occlusion
Typical loading phase: 3–6 monthly injections
Approximate maintenance: Intervals of up to 16 weeks if there is a response
Interval-determining factor: Resolution of macular edema
Condition: Myopic neovascularization
Typical loading phase: 1–3 injections
Approximate maintenance: As needed, based on disease activity
Interval-determining factor: Activity of the neovascular membrane
In routine clinical practice, the frequency of intravitreal anti-VEGF injections for eyes with diabetic macular edema ranges from 2.2 to 4.4 injections per year. (Long-term Treatment Patterns for Diabetic Macular Edema - Ophthalmology Retina) (Ophthalmology Retina, 2024; DOI: 10.1016/j.oret.2024.05.008).
Optical coherence tomography (OCT) is the key test that guides treatment decisions. It is a noninvasive medical imaging technology, similar to ultrasound and magnetic resonance imaging, that uses reflected light to produce detailed cross-sectional and three-dimensional images of the eye. (Treatment of ocular neovascularization using anti-VEGF proteins)
Treatment response is measured with OCT, which produces an image of the retina in less than a minute, showing how much fluid is present. (Anti-VEGF Treatments for Wet Age-Related Macular Degeneration)
OCT is essential for the early diagnosis and long-term monitoring of conditions such as AMD and diabetic retinopathy. It allows the detection of subretinal fluid in AMD and the measurement of diabetic macular edema. The ability to track microstructural changes over time supports treatment planning and evaluation of its effectiveness. (What Is Optical Coherence Tomography (OCT) Eye Test?)
Retinal fluid detected on OCT has the strongest documented impact on clinical outcomes. In particular, intraretinal fluid is associated with poorer visual outcomes. The consistency of these findings can inform personalized clinical decisions, such as starting treatment early and proactive monitoring. (Prognostic Optical Coherence Tomography Biomarkers in Neovascular Age-Related Macular Degeneration)
In simple terms: OCT allows the specialist to see whether the eye still has disease activity before that activity translates into symptoms noticed by the patient. It is the difference between acting in time and waiting until the damage is more difficult to reverse.
Some vision changes need attention before your next follow-up appointment. Recognizing them can make a difference in your visual prognosis.
Contact your clinic promptly if you notice any of the following:
It is important to distinguish these acute changes from the normal day-to-day variations many patients experience during treatment. Mild, stable symptoms can be discussed at your next scheduled appointment; sudden changes should not wait.
If you experience sudden vision loss, severe pain, or significant redness after an injection, seek medical attention that same day. Do not delay.
Anti-VEGF treatment works best when patients take an active role. This does not mean living a restrictive life, but making informed and consistent choices.
Managing underlying conditions: In diabetic macular edema, controlling blood glucose and blood pressure directly affects disease activity. A well-controlled glycated hemoglobin (HbA1c) level reduces stress on the retinal blood vessels.
Attending all appointments: Missing a follow-up assessment may mean that active retinal fluid is not detected in time. Consistent attendance during the loading phase is important because it lays the groundwork for the long-term treatment response. (Anti-VEGF Injections for Macular Degeneration: A Patient Guide)
Self-monitoring with the Amsler grid: Many specialists recommend checking your central vision at home using this grid of lines. If the lines become distorted from one day to the next, report it. Ask your doctor if you already have one.
Sun protection: Wearing UV-filtering lenses may contribute to overall retinal care, especially for patients with AMD.
General habits: Not smoking, eating a balanced diet, and maintaining a healthy weight are factors that, while they do not replace treatment, support the vascular health the retina needs.
If you have questions about your current treatment or would like a retina specialist to review your case, you can request an assessment at High Vision. The team can guide you on the diagnostic tests appropriate for your situation.
Most patients report minimal discomfort. The procedure is performed with topical anesthesia (eye drops), so pain during the injection is generally mild or absent. You may feel brief pressure. Post-injection discomfort usually resolves within a few hours.
The duration varies depending on the medication and the individual eye’s response. In general, the effect lasts between four and sixteen weeks. Follow-up OCT helps determine when the eye needs treatment again, before vision deteriorates.
Anti-VEGF medications control disease activity; they do not cure it. Their goal is to stabilize vision and, in many cases, improve it. These medications slow the disease, but they do not cure the underlying condition. (Comparison of Anti-VEGF Treatments for Wet AMD - American Academy of Ophthalmology) Ongoing follow-up is part of the treatment plan.
Missing an appointment may allow retinal fluid to reactivate without being detected. In diseases such as wet AMD or diabetic macular edema, this reactivation can cause vision loss that may be harder to recover later. If you cannot attend, notify us in advance so we can reschedule as soon as possible.
No. The interval varies from case to case and according to the response to a particular medication. (Comparison of Anti-VEGF Treatments for Wet AMD - American Academy of Ophthalmology) Two patients with wet AMD may require very different treatment frequencies. The plan is adjusted at each visit based on OCT findings and visual acuity.
It is advisable not to drive on the day of the procedure, since dilating drops may be used and can temporarily affect your vision. Most patients can resume light daily activities within a few hours, but it is best to follow your treating physician’s specific instructions.